Comparative Pharmacology
Head-to-head clinical analysis: AXID versus TRITEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID versus TRITEC.
AXID vs TRITEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive, reversible inhibition of histamine at H2-receptors on gastric parietal cells, reducing gastric acid secretion by blocking the H2-receptor-mediated activation of adenylate cyclase and subsequent cAMP production.
H2-receptor antagonist; competitively inhibits histamine at H2 receptors of gastric parietal cells, reducing basal and stimulated gastric acid secretion.
300 mg orally once daily at bedtime or 150 mg orally twice daily. Max 300 mg/day.
300 mg orally twice daily for 14 days; alternative: 600 mg orally once daily for 14 days.
None Documented
None Documented
1.5-2.5 hours (prolonged in renal impairment: up to 4-5 hours if CrCl <20 mL/min)
2-3 hours (prolonged to 4-5 hours in elderly or renal impairment, CrCl <30 mL/min)
Renal (60% unchanged), biliary (30%), fecal (<10%)
Renal: 60% unchanged; fecal: 35% (mainly metabolites)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist/Antimicrobial Combination